You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHMPL-004
Accession NumberDB05767
TypeSmall Molecule
GroupsInvestigational
DescriptionHMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII410105JHGR
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationInvestigated for use/treatment in ulcerative colitis.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionHMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-α, IL-1β and IL-6. HMPL-004 was demonstrated to inhibit TNF-α and IL-1β production in cell-based assays. HMPL-004 is also able to inhibit NF-kB activation. NF-kB is a family of transcriptional factors that regulate a wide spectrum of genes critically involved in host defence and inflammation. The mechanism of action of HMPL-004 was further supported in laboratory IBD animal models. Treatment of IBD rats with HMPL-004 caused a significant drop in plasma cytokine concentrations, including TNF-α and IL-1β.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tumor necrosis factorProteinunknownNot AvailableHumanP01375 details
Interleukin-1 betaProteinunknownNot AvailableHumanP01584 details
Interleukin-6ProteinunknownNot AvailableHumanP05231 details
Nuclear factor NF-kappa-B p100 subunitProteinunknownNot AvailableHumanQ00653 details
Nuclear factor NF-kappa-B p105 subunitProteinunknownNot AvailableHumanP19838 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with 5-androstenedione.Experimental, Illicit
AbciximabHMPL-004 may increase the anticoagulant activities of Abciximab.Approved
AcebutololHMPL-004 may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Aceclofenac.Approved
AcenocoumarolHMPL-004 may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with HMPL-004.Approved, Vet Approved
AclarubicinHMPL-004 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with HMPL-004.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Alendronic acid.Approved
AliskirenHMPL-004 may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololHMPL-004 may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with HMPL-004.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Amcinonide.Approved
AmikacinHMPL-004 may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideHMPL-004 may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinHMPL-004 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodHMPL-004 may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Anisodamine.Investigational
annamycinHMPL-004 may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with HMPL-004.Approved
Antithrombin III humanHMPL-004 may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704HMPL-004 may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanHMPL-004 may increase the anticoagulant activities of Apixaban.Approved
ApramycinHMPL-004 may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with HMPL-004.Approved, Investigational
ArbekacinHMPL-004 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinHMPL-004 may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanHMPL-004 may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololHMPL-004 may decrease the antihypertensive activities of Arotinolol.Approved
AtenololHMPL-004 may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with HMPL-004.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with HMPL-004.Approved
BalsalazideHMPL-004 may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminHMPL-004 may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololHMPL-004 may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with HMPL-004.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with HMPL-004.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with HMPL-004.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with HMPL-004.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Betamethasone.Approved, Vet Approved
BetaxololHMPL-004 may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Betulinic Acid.Investigational
BevantololHMPL-004 may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with HMPL-004.Approved, Investigational
BisoprololHMPL-004 may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinHMPL-004 may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololHMPL-004 may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with HMPL-004.Approved
BucillamineThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Bucillamine.Investigational
BucindololHMPL-004 may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Budesonide.Approved
BufuralolHMPL-004 may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideHMPL-004 may decrease the diuretic activities of Bumetanide.Approved
BupranololHMPL-004 may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with HMPL-004.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with HMPL-004.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with HMPL-004.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with HMPL-004.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with HMPL-004.Approved, Vet Approved, Withdrawn
CarteololHMPL-004 may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolHMPL-004 may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with HMPL-004.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Celecoxib.Approved, Investigational
CeliprololHMPL-004 may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinHMPL-004 may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with HMPL-004.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with HMPL-004.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with HMPL-004.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with HMPL-004.Approved
CinoxacinHMPL-004 may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinHMPL-004 may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidHMPL-004 may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with HMPL-004.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Curcumin.Investigational
CyclosporineHMPL-004 may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with D-Limonene.Investigational
Dabigatran etexilateHMPL-004 may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinHMPL-004 may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidHMPL-004 may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinHMPL-004 may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinHMPL-004 may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with HMPL-004.Approved
DextranHMPL-004 may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40HMPL-004 may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70HMPL-004 may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75HMPL-004 may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with HMPL-004.Approved, Vet Approved
DicoumarolHMPL-004 may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with HMPL-004.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with HMPL-004.Approved
DihydrostreptomycinHMPL-004 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with HMPL-004.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with HMPL-004.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with HMPL-004.Approved
DoxorubicinHMPL-004 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneHMPL-004 may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when HMPL-004 is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Ebselen.Investigational
Edetic AcidHMPL-004 may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanHMPL-004 may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with HMPL-004.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with HMPL-004.Approved
EnoxacinHMPL-004 may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinHMPL-004 may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Epirizole.Approved
EpirubicinHMPL-004 may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneHMPL-004 may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with HMPL-004.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with HMPL-004.Approved
EquileninThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Equilin.Approved
EsmololHMPL-004 may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Estrone sulfate.Approved
Etacrynic acidHMPL-004 may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with HMPL-004.Approved, Investigational
Ethyl biscoumacetateHMPL-004 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when HMPL-004 is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with HMPL-004.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with HMPL-004.Vet Approved
FleroxacinHMPL-004 may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with HMPL-004.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fludrocortisone.Approved
FluindioneHMPL-004 may increase the anticoagulant activities of Fluindione.Investigational
FlumequineHMPL-004 may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with HMPL-004.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with HMPL-004.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with HMPL-004.Approved, Nutraceutical, Vet Approved
FondaparinuxHMPL-004 may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumHMPL-004 may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with HMPL-004.Experimental
FormestaneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with HMPL-004.Approved
FramycetinHMPL-004 may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideHMPL-004 may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateHMPL-004 may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinHMPL-004 may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinHMPL-004 may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with HMPL-004.Approved, Withdrawn
GemifloxacinHMPL-004 may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinHMPL-004 may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinHMPL-004 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AHMPL-004 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinHMPL-004 may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HMPL-004 is combined with HE3286.Investigational
HeparinHMPL-004 may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Higenamine.Investigational
HirulogHMPL-004 may increase the anticoagulant activities of Hirulog.Experimental
HydralazineHMPL-004 may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with HMPL-004.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with HMPL-004.Approved
Hygromycin BHMPL-004 may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with HMPL-004.Approved
IbuproxamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Icatibant.Approved
IdarubicinHMPL-004 may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxHMPL-004 may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with HMPL-004.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with HMPL-004.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with HMPL-004.Approved
IndenololHMPL-004 may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with HMPL-004.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Indoprofen.Withdrawn
INNO-206HMPL-004 may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with HMPL-004.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Istaroxime.Investigational
KanamycinHMPL-004 may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with HMPL-004.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with HMPL-004.Approved
LabetalolHMPL-004 may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with HMPL-004.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with HMPL-004.Approved, Investigational
LepirudinHMPL-004 may increase the anticoagulant activities of Lepirudin.Approved
LevobunololHMPL-004 may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinHMPL-004 may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with HMPL-004.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with HMPL-004.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with HMPL-004.Approved
LomefloxacinHMPL-004 may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with HMPL-004.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with HMPL-004.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with HMPL-004.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HMPL-004.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with HMPL-004.Approved
ME-609The risk or severity of adverse effects can be increased when HMPL-004 is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HMPL-004.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with HMPL-004.Approved
MelengestrolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with HMPL-004.Approved, Vet Approved
MesalazineHMPL-004 may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with HMPL-004.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with HMPL-004.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with HMPL-004.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Methylprednisolone.Approved, Vet Approved
MetipranololHMPL-004 may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with HMPL-004.Approved
MetoprololHMPL-004 may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideHMPL-004 may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with HMPL-004.Approved
MizoribineThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with HMPL-004.Approved
MometasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with HMPL-004.Approved
MoxifloxacinHMPL-004 may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HMPL-004.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HMPL-004.Approved
NabumetoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Nabumetone.Approved
NadololHMPL-004 may decrease the antihypertensive activities of Nadolol.Approved
NadroparinHMPL-004 may increase the anticoagulant activities of Nadroparin.Approved
NafamostatHMPL-004 may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with HMPL-004.Approved
Nalidixic AcidHMPL-004 may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with HMPL-004.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when HMPL-004 is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when HMPL-004 is combined with NCX 4016.Investigational
NeamineHMPL-004 may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinHMPL-004 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinHMPL-004 may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Nepafenac.Approved
NetilmicinHMPL-004 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with HMPL-004.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with HMPL-004.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Nitroaspirin.Investigational
NorfloxacinHMPL-004 may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinHMPL-004 may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with HMPL-004.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with HMPL-004.Approved
OlsalazineHMPL-004 may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with HMPL-004.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Orgotein.Vet Approved
OtamixabanHMPL-004 may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with HMPL-004.Approved
OxprenololHMPL-004 may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HMPL-004.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Parecoxib.Approved
ParomomycinHMPL-004 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinHMPL-004 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinHMPL-004 may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololHMPL-004 may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateHMPL-004 may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with HMPL-004.Approved
PhenindioneHMPL-004 may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonHMPL-004 may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with HMPL-004.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with HMPL-004.Approved, Investigational
PindololHMPL-004 may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinHMPL-004 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideHMPL-004 may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with HMPL-004.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with HMPL-004.Approved, Investigational
PlicamycinHMPL-004 may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with HMPL-004.Approved
PractololHMPL-004 may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with HMPL-004.Approved
PrasteroneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of HMPL-004 can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Propacetamol.Approved
PropranololHMPL-004 may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with HMPL-004.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with HMPL-004.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with HMPL-004.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with HMPL-004.Vet Approved
Protein CHMPL-004 may increase the anticoagulant activities of Protein C.Approved
Protein S humanHMPL-004 may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeHMPL-004 may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinHMPL-004 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with HMPL-004.Investigational
PuromycinHMPL-004 may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with HMPL-004.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with HMPL-004.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with HMPL-004.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with HMPL-004.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with HMPL-004.Experimental, Investigational
ReviparinHMPL-004 may increase the anticoagulant activities of Reviparin.Approved
RibostamycinHMPL-004 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Risedronate.Approved, Investigational
RivaroxabanHMPL-004 may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinHMPL-004 may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with HMPL-004.Approved
SalicylamideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with HMPL-004.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with HMPL-004.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with HMPL-004.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with HMPL-004.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Seratrodast.Approved, Investigational
SisomicinHMPL-004 may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolHMPL-004 may decrease the antihypertensive activities of Sotalol.Approved
SP1049CHMPL-004 may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinHMPL-004 may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinHMPL-004 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with HMPL-004.Approved
SpironolactoneHMPL-004 may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with HMPL-004.Investigational
StreptomycinHMPL-004 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinHMPL-004 may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineHMPL-004 may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with HMPL-004.Approved
SulodexideHMPL-004 may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with HMPL-004.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with HMPL-004.Approved, Withdrawn
TacrolimusHMPL-004 may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with HMPL-004.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with HMPL-004.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with HMPL-004.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with HMPL-004.Approved, Investigational
TemafloxacinHMPL-004 may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with HMPL-004.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with HMPL-004.Approved
TepoxalinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with HMPL-004.Approved
TiludronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tiludronate.Approved, Vet Approved
TimololHMPL-004 may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tixocortol.Approved
TobramycinHMPL-004 may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with HMPL-004.Approved
TorasemideHMPL-004 may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with HMPL-004.Approved
TranilastThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with HMPL-004.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with HMPL-004.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Triamcinolone.Approved, Vet Approved
TriamtereneHMPL-004 may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with HMPL-004.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with HMPL-004.Approved
TrovafloxacinHMPL-004 may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with HMPL-004.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinHMPL-004 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with HMPL-004.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with HMPL-004.Approved
WarfarinHMPL-004 may increase the anticoagulant activities of Warfarin.Approved
XimelagatranHMPL-004 may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150HMPL-004 may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with HMPL-004.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with HMPL-004.Withdrawn
ZorubicinHMPL-004 may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein domain specific binding
Specific Function:
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.
Gene Name:
IL1B
Uniprot ID:
P01584
Molecular Weight:
30747.7 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Interleukin-6 receptor binding
Specific Function:
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as ...
Gene Name:
IL6
Uniprot ID:
P05231
Molecular Weight:
23717.965 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB2
Uniprot ID:
Q00653
Molecular Weight:
96748.355 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB1
Uniprot ID:
P19838
Molecular Weight:
105355.175 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24